<DOC>
	<DOCNO>NCT00001428</DOCNO>
	<brief_summary>This protocol evaluate activity 5-Fluorouracil ( FUra ) give 1 hour infusion combination leucovorin ( LV ) interferon IFN alpha-2a patient advance , measurable colorectal cancer .</brief_summary>
	<brief_title>A Phase II Study 5-Fluorouracil Administered One Hour Infusion Combination With Calcium Leucovorin Interferon Alpha-2A Advanced Colorectal Cancer</brief_title>
	<detailed_description>This protocol evaluate activity 5-Fluorouracil ( FUra ) give 1 hour infusion combination leucovorin ( LV ) interferon IFN alpha-2a patient advance , measurable colorectal cancer . IFN alpha-2a give 5 million U/m ( 2 ) SC day 1-6 ; LV , 200 mg/m ( 2 ) , give short infusion 30 minute day 2-6 , follow immediately 1 hour IV infusion FUra day 2-6 . The start dose FUra 425 mg/m ( 2 ) /d ( 1 ) . Cycles repeat three week interval provide granulocyte count platelet count recover &amp; gte ; 1200/microL &amp; gte ; 80,000/microL , respectively , non-hematologic toxicity resolve . The dose FUra adjust accord individual tolerance . Preliminary experience FUra give 1 hour infusion suggest less toxic . The primary goal study determine less toxic regimen retain clinical antitumor activity . FUra plasma sample obtain initial cycle 50 55 minute first 1 hour infusion FUra permit documentation achieve plasma level permit correlation FUra pharmacokinetics clinical toxicity and/or response . Pharmacokinetic sampling repeat dose FUra increase decreased subsequent cycle . Patients stratify accord whether receive prior adjuvant chemotherapy . A two-stage design employ patient prior chemotherapy : If less equal 4 response see among initial 20 previously untreated patient , accrual cease . If great equal 5 response see initial 20 patient , however , accrual expand 40 patient . Fourteen patient receive prior adjuvant chemotherapy ( complete least 6 month prior study entry ) receive prior FUra radiation sensitizer enter . If response see , accrual cohort cease . If great equal 1 response see , accrual may expand 24 patient .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Unresectable primary colorectal adenocarcinoma metastatic recurrent . Objectively measurable disease require . No cerebral metastasis . PRIOR/CONCURRENT THERAPY : Biologic Therapy : No history intolerance interferon alfa ( IFNA ) . At least 4 week since immunotherapy recover . Chemotherapy : No prior chemotherapy metastatic recurrent disease . At least 6 month since adjuvant chemotherapy fluorouracil ( 5FU ) combination levamisole , leucovorin ( CF ) , IFNA Interval waive 5FU ( without CF ) radiosensitizer . No doselimiting toxicity prior 5FU . Endocrine Therapy : Not specify Radiotherapy : At least 2 week since palliative radiotherapy recover . Prior definitive pelvic whole upper abdominal radiotherapy allow absence current radiation enteritis . Surgery : Prior surgery allow adequate healing/recovery Patient Characteristics : Age : 18 . Performance status : ECOG 0 1 . Hematopoietic : AGC least 2,000 . Platelets least 100,000 . Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : No MI within past year . No active ischemic heart disease . No NYHA class III/IV status . No symptomatic arrhythmia . OTHER : No requirement pharmacologic steroid dos inflammatory autoimmune disorder . Physiologic replacement dos steroids allow . No concurrent cimetidine oxypurinol . No HIV antibody . No history seizure disorder . No active infection serious concurrent medical illness would preclude treatment . No second malignancy within 3 year except curatively treat : In situ carcinoma cervix , Basal cell carcinoma skin . No pregnant nursing woman . Effective contraception require fertile patient .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Cytokine</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Palliation</keyword>
	<keyword>Solid Tumor</keyword>
</DOC>